Background: Laparoscopy results in pathophysiologic changes and potentiates a neurohormonal stress response which increases systemic vascular resistance, mean arterial blood pressure, and heart rate and the aim of present study was to evaluate the effect of dexmedetomidine in high risk cardiac patients undergoing laparoscopic cholycystectomy. Methods: The study included 80 patients [cardiac patient with ASA physical status III-IV], and scheduled for elective laparoscopic cholycystectomy. The patients were classified randomly into two groups: Group D: The patients received a loading dose of 1 lg/kg dexmedetomidine over 15 min before induction and maintained with 0.3 lg/kg/h infusion during the procedure. Group C: The patients received an equal volume of normal saline. Results: The heart rate increased greatly after induction in the control group compared to the group D (P < 0.05) and the heart rate remained elevated during the procedures and postoperatively. There was an attack of tachycardia affected 4 patients in group D and 10 patients in group C and the comparison was significant (P = 0.044). The mean arterial blood pressure increased greatly after induction in the control group compared to the group D (P < 0.05) and the mean arterial blood pressure remained elevated during the procedures and post-anesthesia care unit The total fentanyl dose was higher in the group C patients more than group D (P < 0.001). The end-tidal sevoflurane was lower in group D patients than group C patients (P < 0.001). Conclusion: Dexmedetomidine is safe for cardiac patients undergoing laparoscopic cholycystectomy. It minimized the changes in heart rate and blood pressure and decreased the total dose of fentanyl and end-tidal sevoflurane and the requirement for medications in high risk cardiac patients.
Introduction
Laparoscopy has now become the standard technique for cholycystectomy. Pneumoperitoneum required for laparoscopy results in pathophysiologic changes and potentiates a neurohormonal stress response which increases the systemic vascular resistance, arterial blood pressure, and heart rate [1] [2] [3] , and reduces the venous return, preload, stroke volume, and cardiac output [4, 5] . These factors increase the afterload and decreases the preload which are tolerated in ASA I and II patients [6, 7] , and poorly tolerated by patients with cardiac dysfunction (ASA III-IV) [8, 9] .
Dexmedetomidine is a highly selective alpha-2 agonist that provides sedation and analgesia. It activates pro-survival kinases and attenuates ischemia and hypoxic injury, including cardioprotection [10] . Concurrent infusion during surgery reduces anesthetic consumption by 20-50% [11] , and produces a decrease in heart rate and blood pressure that may be advantageous in ischemic heart disease by improving oxygen supply and demand balance [12] .
The aim of the present study was to evaluate the effect of dexmedetomidine on the intraoperative hemodynamic stability in high risk cardiac patients undergoing laparoscopic cholycystectomy.
Methods and patients
After approval from the local ethics committee and obtaining written informed consent in the King Fahd hospital, Saudi Arabia, a study included 80 patients [cardiac patient with ASA physical status III-IV], undergoing elective laparoscopic cholycystectomy through 2012-2014. The inclusion criteria were patients with hypertension, coronary artery disease (ischemic heart disease or percutaneous transluminal coronary angioplasty, coronary artery bypass grafting), poor ventricular function, or valvular disease.
The patients were assessed using New York Heart Association (NYHA) [13] , and American Society of Anesthesiologists Physical Status Score (ASA) [14] . Exclusion criteria included patients with congestive heart failure, obese patients or emergency. All patients were evaluated preoperatively by cardiologists and anesthesiologists. Investigations such as ECG and transthoracic echocardiography were done for all patients for evaluating the function of the myocardium and cardiac valves, diagnosis and treatment of ischemic heart diseases and patients on anticoagulants were managed by cardiologist preoperatively. All patients received their medications for hypertension, ischemic heart disease, or arrhythmia approximately two hours prior to anesthesia induction. The patients were classified randomly by simple randomization through a process of cointossing into two groups:
Group D: The patients received dexmedetomidine as a loading dose of 1 lg/kg over 15 min before induction and maintained with 0.3 lg/kg/h infusion during the procedure.
Group B (control group): The patients received equal amount of normal saline.
Anesthetic technique
For all patients and under local anesthesia, a radial arterial cannula and peripheral venous cannula G 18 or 16 were inserted and central venous line was inserted after induction for administration of inotropic drugs and vasodilators if needed. Anesthesia induction was started by preoxygenation with 100% oxygen, intravenous fentanyl (1-2 lg/kg), etomidate (0.3 mg/kg), and cisatracurium (0.2 mg/kg). After tracheal intubation, the anesthesia was maintained with sevoflurane (1-3%), fentanyl infusion (1-3 lg/kg/h), cisatracurium (1-2 lg/kg/min) and oxygen:air (50:50%).
For all patients, carbon dioxide insufflation was initiated and maintained at 5 L/min and the highest limit of intraabdominal pressure was kept at 10 mmHg and the surgery was done in the supine position. Intraoperative fluids were given cautiously. Intraoperative increased heart rate and systemic hypertension were managed by bolus doses of fentanyl (1-2 lg/kg) and increasing of sevoflurane concentration 1-2%, and if hypertension persists, nitroglycerine infusion 0.5-1 lg/kg/min was started. Intraoperative hypotension was managed by bolus doses of ephedrine 5-10 mg and if persisted, dopamine infusion was started. At the end of the intervention and deflation of peritoneum, dopamine infusion was weaned gradually and discontinued in the operative room. The patients were transferred to post-anesthesia care unit with closed monitoring and observation for 2-4 h. Most of the patients were shifted to the ward, while few patients were transferred to the intensive care unit according to preoperative plan.
Monitoring of patients
The monitors included the heart rate, mean arterial blood pressure (MAP), a continuous electrocardiograph with automatic ST-segment analysis (leads II and V), arterial oxygen saturation, end-tidal carbon dioxide, end tidal sevoflurane, total dose of fentanyl, arterial blood gases. The heart rate and mean blood pressure were serially collected at the baseline; after induction of anesthesia; every 5 min during the procedure; at the end of surgery; and every 5 min in the post-anesthetic care unit. Also the incidence of hypotension, hypertension, tachycardia or bradycardia, and any adverse effects were recorded.
Outcomes
The primary outcome was stability of the hemodynamic status of the patients assessed by changes in the heart rate and blood pressure.
Secondary outcomes were total dose of fentanyl and endtidal sevoflurane %. The safety of the procedure was assessed by the occurrence of any adverse events and the requirements to pharmacological support.
Sample size calculation
Power analysis was performed using Chi square test for independent samples on frequency of patients complaining of perioperative hemodynamic instability, because it was the main outcome variable in the present study. A pilot study was done before starting this study because there are no available data in the literature for the role of dexmedetomidine in high risk cardiac patients undergoing laparoscopic cholycystectomy. The results of the pilot study showed incidence of hemodynamic instability was of 20% in dexmedetomidine group, and 50% in control group. Taking power 0.8 and alpha error 0.05, a minimum sample size of 38 patients was calculated for each group. The total number of patients in each group was 40 to compensate for possible dropouts.
The statistical paragraph in material and methods
Data were statistically described in terms of mean ± standard deviation (±SD), median and range, or frequencies (number of cases) and percentages when appropriate. Comparison of numerical variables between the study groups was done using Student t test for independent samples. For comparing categorical data, Chi square (v 2 ) test was performed. Exact test was used instead when the expected frequency is less than 5. P values less than 0.05 was considered statistically significant.
All statistical calculations were done using computer program SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) release 15 for Microsoft Windows (2006). There was no statistical difference regarding the age, weight, gender, preoperative co-morbidities, ejection fraction and ASA physical status of patients (P > 0.05) ( Table 1) . Table 2 shows the comparison of heart rate between the two groups. The heart rate increased greatly after induction in the group C compared with the group D (P < 0.05) and the heart rate remained elevated during the procedures and post-anesthesia care unit. There was an attack of tachycardia affected 4 patients in group D and 10 patients in group C and the comparison was significant (P = 0.044) ( Table 4) . Table 3 shows the comparison of mean arterial blood pressure of patients between the two groups. The mean arterial blood pressure increased greatly after induction in the group C compared with the group D (P < 0.05) and the mean arterial blood pressure remained elevated during the procedures and post-anesthesia care unit. There was attack of hypertension included 5 patients in group D and 14 patients in group C (P = 0.035). There were 6 patients in group D and 4 patients in group C suffered from hypotension and the comparison was statistically insignificant (P = 0.735) ( Table 4 ). Table 4 shows the intraoperative data of patients. There was no statistical difference regarding the duration of anesthesia (P = 0.846) and end-tidal carbon dioxide (P = 0.530). Ephedrine was need to manage hypotension in 6 patients in group D and 4 patients in group C and the comparison was insignificant (P = 0.735). Dopamine was needed to manage hypotension in 3 patients in group D and 2 patients in group C and the comparison was statistically insignificant (P = 0.213). The total fentanyl dose was higher in the group C more than group D (P < 0.001). The end-tidal sevoflurane was lower in group D patients than group C patients (P < 0.001). There was only one patient in group C suffered from acute myocardial infarction and the patient died through a few hours after infarction.
Results

Discussion
The previous studies evaluated the effect of dexmedetomidine on ASA physical status I-II and there is not any study on cardiac patients ASA III-IV during laparoscopic cholycystectomy; therefore, the present study was done to assess the effect of dexmedetomidine in high risk cardiac patients during laparoscopic cholycystectomy. The present study showed that dexmedetomidine is safe for cardiac patients who underwent laparoscopic cholycystec- tomy. The patients were hemodynamically stable and there were minimal changes in heart rate and arterial blood pressure with dexmedetomidine compared to the control group. There were no changes in the ST-segment during the procedure. There were fewer patients suffering from hypertension with dexmedetomidine than the control group. The total dose of fentanyl and end-tidal sevoflurane decreased greatly with dexmedetomidine than the control group. There was only one mortality case in the control group. The patient was hypertensive preoperatively and hemodynamically stable during the surgery and recovery. After 6 h from transferring to the ward, the patient complained of epigastric pain (not chest pain), and ECG showed massive myocardial infarction. The patient deteriorated rapidly in spite of the inotropic support; therefore, the coronary catheterization could not be done and the patient expired within 4 h later.
Li-rong et al. [15] evaluated the myocardial protective effect of dexmedetomidine during non-cardiac surgery in patients ASA II-III with coronary heart disease undergoing elective upper abdominal surgery. They found that patients were hemodynamic stable and the incidence of tachycardia and myocardial ischemia was significantly lower with dexmedetomidine. A large cohort study included 15,656 non-cardiac surgical cases, of whom 2688 received dexmedetomidine preoperatively or intraoperatively and 12,968 did not receive dexmedetomidine. There was no significant intraoperative hypotension or bradycardia with dexmedetomidine [16] .
Xu et al. [17] studied the effects of dexmedetomidine on perioperative myocardial injury by observing peripheral circulatory changes in myocardial enzyme levels and hemodynamic changes in patients with coronary heart disease undergoing elective hip replacement surgery. Dexmedetomidine reduced myocardial injury and the patients were hemodynamically stable. Sadhu et al. [18] studied 28 patients NYHA II-III with a significant cardiac dysfunction (ejection fraction 20-40%, cardiomyopathy, valvular disease, heart block, prior cardiac interventions) and scheduled for laparoscopic cholycystectomy. The anesthesia was maintained with either sevoflurane or isoflurane without dexmedetomidine. The commonest and significant events were hypertension, hypotension, tachyarrhythmia and bradycardia and the patients required nitroglycerine, epinephrine, norepinephrine, and amiodarone infusion according to the complication and there was one mortality case as a result of acute myocardial infarction (third postoperative day), and other studies showed the same results [19, 20] .
Sidorowicz et al. [21] found that patients ASA II-III who received dexmedetomidine during carotid endarterectomy were hemodynamically stable and there were no fluctuation in the blood pressure compared to patients who did not receive dexmedetomidine.
The present study and other studies showed that dexmedetomidine is protective for the cardiovascular system in cardiac patients undergoing non-cardiac surgery. Dexmedetomidine decreases stress hormones (epinephrine, norepinephrine, vasopressin) during pneumoperitoneum [3, [22] [23] [24] , and these hormones cause tachycardia, hypertension and perioperative myocardial infarction [25] [26] [27] [28] [29] . Also the dexmedetomidine has an antiarrhythmic effect [29] [30] [31] [32] [33] , and decreases the dose of anesthetics and narcotics that may affect the hemodynamic stability in cardiac patients during laparoscopic cholycystectomy [34] [35] [36] .
Against the results of the present study, a meta-analysis study included 840 patients and evaluated the cardiac outcomes of dexmedetomidine following non-cardiac surgery and showed that dexmedetomidine is associated with significant perioperative hypotension, myocardial ischemia and bradycardia and anticholinergic did not reduce the incidence of bradycardia associated with dexmedetomidine [12] .
The present study recognizes some limitations such as a being single center study as well the small number of patients.
Conclusion
Dexmedetomidine is safe for cardiac patients undergoing laparoscopic cholycystectomy. It minimized the changes in heart rate and blood pressure and decreased the total dose of fentanyl, end-tidal sevoflurane and the requirement for medications in high risk cardiac patients without complications related to dexmedetomidine.
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